Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show, Webcast

Zymeworks Announces Participation in Upcoming Investor Conferences


Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will participate in upcoming investor conferences.

Fireside chats will be webcast live with dial-in details and webcast replays available on Zymeworks' website at http://ir.zymeworks.com/events-and-presentations.

About Zymeworks Inc.

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks' suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks' lead clinical candidate, zanidatamab, is a novel Azymetrictm HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks' second clinical candidate, ZW49, is a novel bispecific HER2?targeted antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks' proprietary ZymeLinktm linker and cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with global biopharmaceutical companies. For more information on our ongoing clinical trials visit www.zymeworksclinicaltrials.com. For additional information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on Twitter.


These press releases may also interest you

at 22:29
Juewei brand meat and vegetable products recalled due to Listeria monocytogenes
Product: Meat and vegetable products Issue: Food - Microbial Contamination - Listeria Distribution:British Columbia See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA)

at 22:03
Contract Research Organization Services Market Projected to Reach $184.21 billion by 2030 - Exclusive Report by 360iResearch
The report titled "Contract Research Organization Services Market by Type (Clinical Research Services, Consulting Services, Data Management Services), Trial Phase (Phase I, Phase II, Phase III), Therapeutic Area, Molecule Type, End-User - Global...

at 21:30
GREENBROOK TMS REPORTS FISCAL YEAR 2023 OPERATIONAL AND FINANCIAL RESULTS
Greenbrook TMS Inc. ("Greenbrook" or the "Company") today announced its fiscal year ended December 31, 2023 ("Fiscal 2023") operational and financial results. All values in this news release are in United States dollars, unless otherwise stated....

at 20:25
AHF Praises Colombia for Putting Lives Before Pharma Greed
AIDS Healthcare Foundation applauds the government of Colombia for issuing a compulsory license on HIV drug dolutegravir, which will allow the country to access affordable generic versions of the treatment as an alternative to the costly branded...

at 20:12
BCACC Deputy Registrar, Kathy Lauriente, honoured with Distinguished Service Award from Thompson Rivers University (TRU)
BCACC is pleased to announce that its Deputy Registrar, Kathy Lauriente, has been honoured with the Distinguished Service Award from Thompson Rivers University. The award recognizes stellar contributions to the University, community, and the public...

at 19:29
Suffolk DBT Expands to Meet the Growing Need for Self-Harm, Suicidal Thoughts, and Depression Therapy.
Suffolk DBT is proud to announce the completion of their initial expansion to accommodate the growing need for DBT therapy...

More news about Health...


News published on and distributed by: